Revenue Performance - Revenue for Q1 FY26 was $19.4 million, representing a 52% increase compared to the prior year period[7] - The company increased its FY26 revenue guidance to $88 million, reflecting a growth of 47% compared to FY25[5] - A total of 4,205 prescriptions were written for the ASSURE® system, marking a 51% increase year-over-year[7] Profitability and Loss - GAAP net loss for Q1 FY26 was $25.8 million, compared to a net loss of $20.3 million in the prior year period[7] - Adjusted EBITDA loss was $19.4 million in Q1 FY26, compared to a loss of $15.7 million in the prior year period[7] Gross Margin - Gross margin expanded to 45.7% in Q1 FY26, up from 32.9% in the prior year period[7] Cash Position - Cash and cash equivalents totaled $201.2 million as of July 31, 2025[7] Operating Expenses - Operating expenses for Q1 FY26 were $37.7 million, including $2.9 million of non-recurring costs related to being a new public company[7] - The increase in operating expenses was attributed to growth in expenses related to commercial and revenue cycle resources[7] Growth Drivers - The company experienced revenue growth driven by higher market share with existing customers and activation of new accounts[7]
Kestra Medical Technologies Ltd(KMTS) - 2026 Q1 - Quarterly Results